|
|
Additional Information
Report Excerpt
6.8.2 Nucynta ER Sales Forecast, 2012-2022
The global sales for Nucynta ER in 2011 were estimated at $51m. Nucynta ER was launched in 2011 and will achieve strong sales throughout the forecast period. Visiongain believes it will reach blockbuster status by 2017, with a CAGR of 65.4% from 2011-2017 (Table 6.11 and Figure 6.10). Nucynta ER’s success will be driven by its efficacy in both neuropathic and nociceptive pain conditions. As a result, it is expected to be prescribed for conditions involving both pain types, such as chronic lower back pain. Its opioid-sparing effects and reduced potential for abuse will also be key clinical advantages for Nucynta ER in neuropathic pain conditions that require long-term management. In addition the experience of Johnson and Johnson within the US pain market will increase sales in the US.
Companies Listed
AB Science
Abbott Laboratories
AcelRx Pharmaceuticals
Actavis
Acura Pharmaceuticals
Allergan
Almirall
Alpharma
ALZA Corporation
American Council for Headache Education
Amgen
Anesiva
Aoxing Pharmaceuticals
Apotec
Apotex
Arcion Therapeutics
Astellas Pharma
AstraZeneca
Avanir Pharmaceuticals
Bayer
BioDelivery Sciences
Biogen Idec
Biovail Corporation
Bristol-Myers Squibb
Britannia Pharmaceuticals
CeNeS Pharmaceuticals
Centocor Ortho Biotech
China Aoxing
CK Life Sciences
Collegium Pharmaceutical
CoLucid Pharmaceuticals
Dainippon
Dara Biosciences
Depomed
Descartes Therapeutics
Dr. Reddy's Laboratories
Durect
Eisai
Eli Lilly
Endo Pharmaceuticals
EpiCept
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Forest Pharmaceuticals
Galderma
Genentech
Genmab
GlaxoSmithKline (GSK)
Grünenthal
Horizon Pharma
Human Genome Sciences
Insys Therapeutics
International Association for the Study of Pain (IASP)
Ipsen
IVAX Pharmaceuticals
Janssen Pharmaceuticals
Johns Hopkins University
Johnson and Johnson (J&J)
King Pharmaceuticals
Ligand Pharmaceuticals
Lundbeck
MAP Pharmaceuticals
Merck & Co.
Merck Serono
Mitsubishi Tanabe Pharma
Mylan
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
Nektar Therapeutics
NeurAxon
NeurogesX
Neurotune
Newron Pharmaceuticals
NicOx Pharmaceuticals
Novartis
NuPathe
Nuvo Research
Omeros
Ono Pharmaceutical
Organon
Ortho-McNeil
Pacira Pharmaceuticals
Pain Therapeutics
Paion
Par Pharmaceuticals
Penwest
Pfizer
Pharmacia
PLx Pharma
Pozen
PriCara Pharmaceuticals
Procter & Gamble
Proteus
Purdue Pharma
QRxPharma
Ranbaxy
Ratiopharm
Rigel Pharmaceuticals
Roche
Schering Plough
Shire
SkyePharma
Solvay Pharmaceuticals
Spinifex Pharmaceuticals
Stada Pharmaceuticals
Sun Pharmaceuticals
Syntaxin
Takeda
Teikoku
Teva Pharmaceutical Industries
The Arthritis Foundation
The International Diabetes Federation (IDF)
The Neuropathy Association
The World Health Organization (WHO)
UCB
University of Queensland
US Census Bureau
US Society for Neuroscience
US WorldMeds
Valeant Pharmaceuticals International
Watson Pharmaceuticals
WEX Pharmaceuticals
Wyeth (now part of Pfizer)
Xenoport
Zars Pharmaceuticals
Zenyaku Kogyo
Zogenix
More Global CNS/Neurology reports
Global Deep Brain Stimulator Market 2012-2016 by Infiniti Research Limited
Global Deep Brain Stimulator Market 2012-2016
TechNavio's analysts forecast the Global Deep Brain Stimulator market to grow at a CAGR of 16.99 percent over ...
Anorexia Nervosa Global Clinical Trials Review, H1, 2013 by GlobalData
Anorexia Nervosa Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, “Anorexia Nervosa Global Clinical Trials Review, H1, 2013 provides data on the Anorexia Nervosa ...
Dyslexia Global Clinical Trials Review, H1, 2013 by GlobalData
Dyslexia Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, “Dyslexia Global Clinical Trials Review, H1, 2013 provides data on the Dyslexia clinical trial scenario. ...
Disease and Therapy Review: Generalized Anxiety Disorder (GAD) by Timely Data Resources, Inc.
See all reports like this >>The Generalized Anxiety Disorder (GAD) Disease and Therapy Review provides an overview of the disease and related conditions, with prevalence numbers and percentages for major ...
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
- Diseases & Conditions
- Pain
- Arthritis
- Pharmaceuticals
- Manufacturing, Packaging & Detailing
- Research & Development
- Drug Discovery
- Therapeutic Area
- CNS/Neurology
CNS/Neurology Reports
